Luther King Capital Management (LKCM)
SCPH

Luther King Capital Management (LKCM)’s scPharmaceuticals SCPH Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,128,391
Closed -$12.1M – 623
2025
Q3 		$12.1M Sell
2,128,391
-1,412,779
-40% -$7.23M 0.05% 159
2025
Q2 		$13.5M Buy
3,541,170
+420,000
+13% +$1.3M 0.06% 151
2025
Q1 		$8.21M Buy
3,121,170
+263,260
+9% +$857K 0.04% 174
2024
Q4 		$10.1M Buy
2,857,910
+632,120
+28% +$2.42M 0.04% 161
2024
Q3 		$10.1M Buy
2,225,790
+20,650
+0.9% +$99.9K 0.04% 158
2024
Q2 		$9.59M Buy
2,205,140
+752,005
+52% +$3.3M 0.04% 158
2024
Q1 		$7.29M Buy
1,453,135
+59,610
+4% +$334K 0.03% 178
2023
Q4 		$8.74M Buy
1,393,525
+457,150
+49% +$2.62M 0.04% 161
2023
Q3 		$6.67M Buy
936,375
+377,450
+68% +$2.97M 0.03% 173
2023
Q2 		$5.7M Buy
558,925
+144,425
+35% +$1.51M 0.03% 192
2023
Q1 		$3.76M Buy
+414,500
New +$3.04M 0.02% 232

Luther King Capital Management (LKCM)'s SCPH Position: Q4 2025 in Review

Luther King Capital Management (LKCM) sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 2,128,391 shares — an estimated $12.1M sold.

Luther King Capital Management (LKCM) first reported a position in SCPH in Q1 2023 and held it in 11 quarters. The position peaked at $13.5M in Q2 2025. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

  • Luther King Capital Management (LKCM) reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 2,128,391 scPharmaceuticals shares in Q4 2025, an estimated $12.1M.
  • Luther King Capital Management (LKCM) first reported a position in scPharmaceuticals in Q1 2023 and held it in 11 quarters.
  • Luther King Capital Management (LKCM)'s scPharmaceuticals position peaked at $13.5M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q4 2025, filed 9 Feb 2026.